Discover 1,562 paid clinical trials in Jersey City, New Jersey. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,562
Active & Responsive
Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder
for
Major Depressive Disorder
Location: 34 recruiting locations
Sponsor: Neumora Therapeutics, Inc.
Sex: All
Age: 18 - 65
Code: NCT06058013
Phase3, Recruiting
Active & Responsive
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
for
Atopic Dermatitis
Location: 26 recruiting locations
Sponsor: Hoffmann-La Roche
Sex: All
Age: 18+
Code: NCT06863961
Phase2, Recruiting
Active & Responsive
A Study to Investigate the Efficacy and Safety of Lebrikizumab in Participants With Moderate-to-Severe Atopic Hand and Foot Dermatitis
for
Atopic Hand and Foot Dermatitis
Location: 25 recruiting locations
Sponsor: Eli Lilly and Company
Sex: All
Age: 12+
Code: NCT06921759
Phase3, Recruiting
Active & Responsive
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma
for
Asthma
Location: 61 recruiting locations
Sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Sex: All
Age: 12+
Code: NCT06664619
Phase3, Recruiting
Active & Responsive
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
for
Recurrent Endometrial Carcinoma,
Location: 219 recruiting locations
Sponsor: National Cancer Institute (NCI)
Sex: Female
Age: 18+
Code: NCT05554328
Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
for
Metastatic Castration-resistant Prostate Cancer
Location: 40 recruiting locations
Sponsor: Celgene
Sex: Male
Age: 18+
Code: NCT06764485
Phase3, Recruiting
Active & Responsive
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
for
Relapsing Multiple Sclerosis (RMS)
Location: 61 recruiting locations
Sponsor: Novartis Pharmaceuticals
Sex: All
Age: 18 - 70+
Code: NCT06869785
Phase3, Recruiting
Active & Responsive
WATER IV Prostate Cancer
for
Localized Prostate Cancer
Location: 19 recruiting locations
Sponsor: PROCEPT BioRobotics
Sex: Male
Age: 45+
Code: NCT06651632
Recruiting
Active & Responsive
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
for
PIK3CA Mutation, Solid Tumor, Adult,
Location: 19 recruiting locations
Sponsor: Relay Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT05216432
Phase1, Recruiting
Active & Responsive
SEAL™IT: Saccular Endovascular Aneurysm Lattice System Interventional Pivotal Trial